Menu
← Oncology Approval Tracker
FDA DECISION ·
Xtandi
enzalutamide · Astellas Pharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For nonmetastatic castration-sensitive prostate cancer with biochemical recurrence and a high risk of metastasis.
LAMPGEN ANALYSIS
Why it matters
The expansion addresses a disease state defined by biochemical recurrence before metastases are detectable.
What research teams should watch
Capture PSA kinetics and staging evidence to distinguish this group from metastatic or castration-resistant populations.
PRIMARY RECORDS